Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.63 |
| ▸ | MMP13 | P45452 | 8/20 | 0.63 |
| ▸ | MMP9 | P14780 | 7/20 | 0.63 |
| ▸ | MMP3 | P08254 | 7/20 | 0.63 |
| ▸ | MMP1 | P03956 | 6/20 | 0.63 |
| ▸ | MMP7 | P09237 | 6/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801083 | 1.00 | MMP2 (0.63) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7541195 | 0.87 | MMP2 (0.51) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL12466926 | 0.83 | MMP2 (0.66) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6795703 | 0.81 | CTSL (0.53) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL2161562 | 0.81 | MMP2 (0.91) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6797666 | 0.81 | MMP2 (0.91) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL14943559 | 0.81 | MMP2 (0.71) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL3842066 | 0.81 | MMP2 (0.91) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6800775 | 0.81 | MMP9 (0.52) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7406967 | 0.77 | MMP2 (1.00) | MMP2MMP13MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | MMP2 4466/4885MMP13 4574/4885MMP9 4812/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | MMP2 4374/4885MMP13 4520/4885MMP9 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.